Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
January 25, 2023 09:00 ET
|
Adhera Therapeutics, Inc.
Data will be instrumental in upcoming Phase 2 clinical trial of MLR-1023, Adhera’s novel Type 1 Diabetes drug candidateCompany moving forward with application to transition from OTC to NASDAQ Baton...